中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
25期
170-171
,共2页
急性心肌梗死%普佑克%溶栓
急性心肌梗死%普祐剋%溶栓
급성심기경사%보우극%용전
Acute myocardial infarction%PuYouKe%Thrombolysis
目的：观察普佑克（注射用重组人尿激酶原）治疗 ST 段抬高型急性心肌梗死的疗效和安全性。方法30例符合入选标准的患者给予普佑克静脉溶栓后，观察患者的临床症状，心肌酶谱，心电图的变化及不良反应的出现。结果冠状动脉总再通率达90%(27/30)，30例患者溶栓后从发病至溶栓在1～3 h 内者8例，再通8例(100%)，3～6 h者19例，再通17例(89.4%),6～12 h 者3例,再通1例(33.3%)。结论急性 ST 段抬高型心肌梗死早)：使用普佑克静脉溶栓疗效好,安全性高，且与时间呈正相关。
目的：觀察普祐剋（註射用重組人尿激酶原）治療 ST 段抬高型急性心肌梗死的療效和安全性。方法30例符閤入選標準的患者給予普祐剋靜脈溶栓後，觀察患者的臨床癥狀，心肌酶譜，心電圖的變化及不良反應的齣現。結果冠狀動脈總再通率達90%(27/30)，30例患者溶栓後從髮病至溶栓在1～3 h 內者8例，再通8例(100%)，3～6 h者19例，再通17例(89.4%),6～12 h 者3例,再通1例(33.3%)。結論急性 ST 段抬高型心肌梗死早)：使用普祐剋靜脈溶栓療效好,安全性高，且與時間呈正相關。
목적：관찰보우극（주사용중조인뇨격매원）치료 ST 단태고형급성심기경사적료효화안전성。방법30례부합입선표준적환자급여보우극정맥용전후，관찰환자적림상증상，심기매보，심전도적변화급불량반응적출현。결과관상동맥총재통솔체90%(27/30)，30례환자용전후종발병지용전재1～3 h 내자8례，재통8례(100%)，3～6 h자19례，재통17례(89.4%),6～12 h 자3례,재통1례(33.3%)。결론급성 ST 단태고형심기경사조)：사용보우극정맥용전료효호,안전성고，차여시간정정상관。
Objective To observe the efficacy and safety of the treatment of ST segment elevation acute myocardial infarction by observing the effect of the treatment of patients with acute myocardial infarction. Methods 30 patients who were treated with the standard of the patients were treated with intravenous thrombolytic therapy. The clinical symptoms, myocardial enzyme spectrum, ECG changes and adverse reactions were observed. Results The total coronary artery patency rate was 90% (27/30). 8 patients were followed up for 17 patients (19), 8 to 6 h (100%), 3 cases (89.4%), 6 cases (12), 1 cases (33.3%). Conclusion In the early stage of acute ST segment elevation myocardial infarction, the effect is good and the safety is high. And was positively correlated with time.
